Supported by: Genentech, A Member of the Roche Group
This program will provide an overview of HCC disease and staging, IMbrave150 including the clinical trial design, patient characteristics, pivotal efficacy and safety data, and exploratory subgroup ana

Supported by: Albireo Pharma, Inc., an Ipsen Company
This presentation will focus on two rare, genetic cholestatic liver diseases: Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC). Drs. Mohammad (Vanderbilt University) an

Supported by: Madrigal Pharmaceuticals
This session will explore several emerging concepts in NASH including: (1) epidemiology and comorbidities, (2) pathophysiology and the role of lipotoxicity in the liver, (3) morbidity and mortality, (4) patient iden

Supported by: Becton, Dickinson and Company 
This symposium will explore the interdisciplinary relationship between Hepatology and Interventional Radiology in treating patients with non-malignant ascites.  Dr. Michael Charlton and Dr. George Behrens will

Supported by: FUJIFILM Healthcare Americas Corporation
CC surveillance is associated with reduced HCC mortality. However, ultrasound has insufficient sensitivity for early tumor detection, prompting increasing interest in blood-based biomarkers. In this

Supported by: E-Scopics
Come “See” how Hepatoscope two-dimensional ultrasound tools can shift the paradigm of early detection and monitoring of MASLD-MASH. With Hepatoscope, E-Scopics brings LSM and a complete quantification suite of Ultrasound Imaging i

Supported by: GSK
Cholestatic pruritus is often considered a significant symptom associated with many liver diseases. This event aims to educate on treating pruritus in parallel to treating the disease, assessing QoL, and scoring and tracking your patien

Columbia University Irving Medical Center

Henry Ford Health

UT Southwestern Medical Center